Johnson & Johnson
$670.11B- Market cap
- $641.88B
- Debt
- +$47.94B
- Cash
- −$19.71B
Capital structure 93% equity / 7% debt · EV / Revenue 7.11x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $641.88B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: JNJ stock price near parity vs STE $266.35 current versus $295.50 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STE's multiple
Implied fair value · at JNJ's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 93% equity / 7% debt · EV / Revenue 7.11x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 91% equity / 9% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Johnson & Johnson · implied price per share
Bear
$93.96
Base
$115.89
Bull
$146.14
STERIS plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe JNJ will re-rate towards STE-implied earnings multiple or will sustain superior margins and high ROIC, then buy JNJ because it shows ~6.6% upside to the implied P/E price ($242.36) while delivering materially higher gross margin (69.1% vs 44.0%), operating margin (24.3% vs 15.9%) and ROIC (25.3% vs 10.3%).
JNJ's current price of $227.26 is about 6.6% below STE-implied P/E implied price of $242.36, implying modest upside if multiples converge. The gap is driven by JNJ trading at a lower P/E (39.3x) than STERIS (41.9x) even though JNJ is richer on revenue and EV/EBITDA multiples.
Supporting Metrics